快驗保 MED 深 滬
已收盤 07-02 16:00:00 美东时间
10.96
-0.070
-0.63%
華盛通- 最 高11.19
- 今 開10.98
- 成交量 27.88万股
- 最 低 10.91
- 昨 收 11.03
- 總市值 1.22亿
- 52周最高 15.37
- 市盈率 靜 --
- 換手率 2.51%
- 52周最低 9.22
- 委 比 -18.32%
- 總股本 1111.91万
- 歷史最高 321.22
- 量 比 0.53
- 振 幅 2.54%
- 歷史最低 -17.07
- 每 手 1
- 風險率 1.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, making standard weight management programs ineffective. Women should focus on visceral fat and lean mass retention rather than scale weight. Sleep disruption, stress, and hormonal variability further complicate self-directed programs. OPTA VIA's clinically supported metabolic health programs target visceral fat while preserving lean mass, with stud...
06-11 11:00
What Science-Backed Subscription Health Programs Measure Differently
The weight loss and weight management market was valued at $31.07 billion in 2025 and is expected to surpass $45 billion by 2030. Many programs use terms like "clinically studied" or "science-backed" without specifying what was measured or how. Dual-energy X-ray absorptiometry (DXA) scanning, the clinical gold standard for body composition, provides more precise measurements than BMI or scale weight. OPTA VIA's study showed a 92.3% completion rat...
06-11 11:00
Medifast Announces New CEO and Leadership Transition
The latest announcement is out from Medifast ( ($MED) ). On May 19, 2026, Medif...
05-27 05:23
Medifast appoints Nicholas Johnson as CEO
Medifast (MED) has appointed Nicholas Johnson as chief executive officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as chairman of the board. Source: Pr...
05-27 04:17
Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation
OPTAVIA's weight loss program emphasizes body composition, targeting visceral fat reduction and lean mass preservation for long-term metabolic health. Structured meal plans, high-quality protein, and coach support are key to achieving sustainable weight loss. Research shows participants in OPTAVIA's program lost 14% visceral fat and retained 98% lean mass in 16 weeks, outperforming independent weight loss attempts.
05-15 17:00
Peer-Reviewed Research Is Redefining Weight Loss Program Standards
The global weight loss industry was valued at $16.3 billion in 2025, but peer-reviewed clinical validation of program outcomes remains inconsistent. OPTA VIA, a science-backed, coach-guided metabolic health system, emphasizes the importance of randomized controlled trials and body composition analysis to ensure clinically proven results. Their studies show that clients on the Optimal Weight 5 & 1 Plan® retained 98% of lean mass and lost 10 times ...
05-15 17:00
Medifast shares are trading higher after the company reported better-than-expected Q1 financial results and reaffirmed its FY2026 EPS and FY2026 sales guidance.
Medifast shares are trading higher after the company reported better-than-expec...
05-05 23:24
Medifast Affirms FY2026 GAAP EPS Guidance of $(2.75)-$(1.55) vs $(1.98) Est; Affirms FY2026 Sales Guidance of $270.000M-$300.000M vs $273.700M Est
Medifast (NYSE:MED) affirms FY2026 GAAP EPS guidance from $(2.75)-$(1.55) to $(2.75)-$(1.55) vs $(1.98) analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$300.000 million to $270.000 million-$300.000
05-05 04:08
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
